|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1992-11-13
|
|
pubmed:abstractText |
The prognostic value was determined of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) measured before and after endocrine treatment in 57 patients with newly diagnosed Stage D2 prostatic cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2302-9
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:1382828-Acid Phosphatase,
pubmed-meshheading:1382828-Aged,
pubmed-meshheading:1382828-Aged, 80 and over,
pubmed-meshheading:1382828-Androgen Antagonists,
pubmed-meshheading:1382828-Follow-Up Studies,
pubmed-meshheading:1382828-Goserelin,
pubmed-meshheading:1382828-Humans,
pubmed-meshheading:1382828-Leuprolide,
pubmed-meshheading:1382828-Male,
pubmed-meshheading:1382828-Middle Aged,
pubmed-meshheading:1382828-Neoplasm Staging,
pubmed-meshheading:1382828-Orchiectomy,
pubmed-meshheading:1382828-Prognosis,
pubmed-meshheading:1382828-Prostate,
pubmed-meshheading:1382828-Prostate-Specific Antigen,
pubmed-meshheading:1382828-Prostatic Neoplasms,
pubmed-meshheading:1382828-Remission Induction,
pubmed-meshheading:1382828-Time Factors,
pubmed-meshheading:1382828-Tumor Markers, Biological
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
|
|
pubmed:affiliation |
Department of Urology, University of Miami School of Medicine, Florida 33101.
|
|
pubmed:publicationType |
Journal Article
|
